Hikma Pharmaceuticals Plc (HIK) will keep its injectable-drug business after concluding a review of the unit, saying the long-term growth potential is excellent. The stock fell as much as 8.4 percent in London. “We are confident that retaining and continuing to invest in this business is the best option for shareholders,” Chief Executive Officer Said Darwazah said in a statement today. “Injectables offers excellent long-term growth prospects and will remain an integral part of our overall growth strategy.” Hikma said March 1 it was considering a possible sale after receiving unsolicited approaches for the business, the second- biggest by volume in the U.S. Amgen Inc. (AMGN) and Novartis AG (NOVN) were among the companies that expressed interest, and the operation could have fetched $2 billion in a sale, two people with knowledge of the matter said last month.
